ADPT

SEC source: 0001209191-21-055586 · doc4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,673,461

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

SEC source: 0001209191-21-055586 · doc4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,673,559

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.02 to 38.99, inclusive.

SEC source: 0001209191-21-055586 · doc4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,678,461

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.15 to 38.73, inclusive.

SEC source: 0001209191-21-055368 · doc4.xml · derivative · entry 6

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 5,000 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-055368 · doc4.xml · nonDerivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.765 to 39.50, inclusive.

SEC source: 0001209191-21-055368 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-055586 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,703,214

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.01 to 39.37, inclusive.

SEC source: 0001209191-21-055586 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,705,218

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-055367 · doc4.xml · derivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,443

Underlying: Common Stock · 495 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-055367 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,036

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-055367 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-055368 · doc4.xml · derivative · entry 5

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,625

Underlying: Common Stock · 9,375 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-055368 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.25 to 39.97, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-055368 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-053766 · doc4.xml · derivative · entry 10

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,480

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.67 to 35.26, inclusive.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,294

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.66 to 34.63, inclusive.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-053971 · doc4.xml · derivative · entry 3

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,084

Underlying: Common Stock · 14,916 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-053971 · doc4.xml · nonDerivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,504

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

SEC source: 0001209191-21-053971 · doc4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

SEC source: 0001209191-21-053766 · doc4.xml · derivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,375

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.57 to 34.49, inclusive.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-053766 · doc4.xml · derivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,270

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.61 to 34.39, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-053766 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-052344 · doc4.xml · derivative · entry 2

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,022

Underlying: Common Stock · 162,022 shares

Expires 2031-08-16

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on August 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-052344 · doc4.xml · nonDerivative · entry 1

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,213

SEC source: 0001209191-21-051275 · doc4.xml · derivative · entry 7

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 10,000 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-051275 · doc4.xml · nonDerivative · entry 5

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.26 to 34.58, inclusive.

SEC source: 0001209191-21-051275 · doc4.xml · nonDerivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,866

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.14 to 34.11, inclusive.

SEC source: 0001209191-21-051275 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-051275 · doc4.xml · derivative · entry 6

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 5,000 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-051275 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.79 to 35.345, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-051275 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-047649 · doc4.xml · derivative · entry 12

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,165

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.82 to 38.36, inclusive.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,855

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.76 to 37.65, inclusive.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-047649 · doc4.xml · derivative · entry 11

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,060

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.41 to 38.13, inclusive.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,955

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.36 to 37.18, inclusive.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-047304 · doc4.xml · derivative · entry 3

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,393

Underlying: Common Stock · 651 shares

Expires 2030-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-047304 · doc4.xml · nonDerivative · entry 2

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,158

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

SEC source: 0001209191-21-047304 · doc4.xml · nonDerivative · entry 1

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

SEC source: 0001209191-21-047649 · doc4.xml · derivative · entry 10

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,955

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.00 to 37.85, inclusive.

SEC source: 0001209191-21-047649 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,982

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.08 to 36.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.